The U.S. Food and Drug Administration announced a request for information on approaches for the design of early-phase clinical trials of ibogaine drug products.

The request seeks comments, data, and information on dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight. The FDA proposes a starting dose justified by available data and not exceeding 10 mg/kg.

Michael Davis, M.D., Ph.D., Director of the FDA Center for Drug Evaluation and Research, said patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.

The Department of Health and Human Services is prioritizing adults with opioid use disorder and adults with post-traumatic stress disorder for federally supported research. The comment period closes on November 20, 2026.

Timeline

In April 2026, the executive order directed agencies to accelerate research into psychedelic medicine. On September 25, 2026, the Health and Human Services Department published a notice titled Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%. On October 1, 2026, the department published a notice titled "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program".

On October 5, 2026, the request for information advances President Trump’s April 2026 executive order on Accelerating Medical Treatments for Serious Mental Illness. The request for information seeks comments, data, and information on dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight.

What's New

Additional reporting indicates the FDA allowed a phase I clinical study of noribogaine hydrochloride, a derivative of ibogaine, to proceed in 2026 following an Investigational New Drug (IND) submission, marking the first U.S. clinical trial of an ibogaine derivative. The FDA’s 2026 press release confirmed that ibogaine derivatives like noribogaine hydrochloride are the first psychedelic compounds to receive IND approval for U.S. clinical trials, marking a shift in regulatory posture toward psychedelic research under the Trump administration. Primary source: federalregister.gov

The FDA has prioritized serotonin-2A agonists and related products, including psilocybin for treatment-resistant depression and methylone for PTSD, under the executive order, reflecting a broader regulatory shift toward psychedelic therapies for serious mental illness. Regulatory frameworks were further defined when the FDA finalized a guidance document in July 2026 titled 'Psychedelic Drugs: Considerations for Clinical Investigations,' outlining scientific and methodological frameworks for trials of psychedelic drugs, including ibogaine, to address therapeutic potential and safety challenges. The FDA’s 2023 draft guidance on psychedelic drug development, which was finalized in 2026, included recommendations for clinical trial design, data collection, and patient monitoring, establishing a regulatory framework that directly informs the current ibogaine trial guidelines. Primary sources: fda.gov, federalregister.gov

Contextual data from Congressional Research Service reports from 2025 showed that 6,000+ veteran suicides annually, with rates twice that of non-veterans, directly informing the focus on opioid use disorder (OUD) in federal ibogaine research initiatives. Recent administrative actions include the Health and Human Services Department publishing a notice titled Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program on 2026-10-01. The department also published a notice titled Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01% on 2026-09-25. Primary sources: federalregister.gov, federalregister.gov (2), govinfo.gov

Why It Matters

Executive Order 14401, issued in April 2026, explicitly linked the opioid crisis to the broader mental health emergency, citing a 37% rise in suicide rates from 2000 to 2018 and emphasizing accelerated research into neuroplastogen-based interventions like ibogaine. This directive establishes a federal priority for investigating compounds that may address these public health challenges. Primary source: fda.gov

The FDA’s actions reflect a structured approach to integrating psychedelic therapies into mainstream medical research. By finalizing guidance and allowing initial trials, the agency has created a pathway for evaluating substances previously outside standard regulatory frameworks. The focus on opioid use disorder and post-traumatic stress disorder targets conditions with significant mortality and morbidity rates, as indicated by federal health data.